Allena Pharmaceuticals, Inc. ROIC

ROIC of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2021 was 0.0% (a NaN% decrease from previous year)
  • Annual ROIC for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual ROIC for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month ROIC ending March 31, 2022 was -1097.85% (a -Infinity% decrease compared to previous quarter)
  • Twelve month trailing ROIC decreased by -Infinity% year-over-year
Trailing ROIC for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-1097.85% 0.0% 0.0% 0.0%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of Allena Pharmaceuticals, Inc.

Most recent ROICof ALNA including historical data for past 10 years.

Interactive Chart of ROIC of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0%
2020 0.0%
2019 0.0%
2018 0.0%
2017 0.0%
2016 0.0%
2015 0.0%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.